Related to FDA Aims to Bridge Communication Gap with Drug Industry During Reviews Through PDUFA V

• FDA Clears Roche's Fully Automated Her2 Gene Status Diagnostic Assay
  
• FDA Committee Votes Against Green-Lighting Novartis’ Gouty Arthritis sBLA
  
• Merck Serono Gives Up on Getting Drug Candidate for Multiple Sclerosis Approved
  
• After Panel’s Vote, Fate of Avastin for MBC in U.S. Rests with FDA Commissioner
  
• FDA Clears Archimedes’ Fentanyl Nasal Spray for Breakthrough Cancer Pain
  
• FDA Issues Transcept a Second CRL for Sleep-Aid Drug Intermezzo
  
• FDA Approves AstraZeneca’s Antiplatelet Drug
  
• FDA Clears Self-Injectable Formulation of BMS’ Rheumatoid Arthritis Drug
  
• Genentech Takes Another Shot at Convincing FDA to Maintain Avastin’s Metastatic Breast Cancer Approval
  
• FDA Issues Adventrx with Complete Response Letter for NSCLC Drug Candidate
  
• FDA Approves Gilead’s Single-Tablet Triple HIV Therapy Complera
  
• FDA Okays Gilead’s San Dimas, CA, Site for Continued Operation
  
• FDA Green-Lights Roche’s Melanoma Drug and Companion Diagnostic
  
• FDA Details Strategy for Overhauling Regulatory Science Used in Review Process
  
• Seattle Genetics’ Antibody-Drug Conjugate Receives FDA Okay to Treat Lymphomas
  
• FDA Sanctions Abbott's Genetic FISH Panel for Leukemia Prognosis
  
• FDA Issues Novartis with CRL Requesting Additional Safety Data on Gouty Arthritis Drug
  
• NuPathe Shares Plunge After Launch of Migraine Patch Delayed
  
• FDA Gives Amgen’s Prolia the Go-Ahead in Two Cancer Therapy-Induced Bone Loss Indications
  
• FDA Details “Reasonable and Feasible” Trial Design for Orexigen’s Obesity Drug Contrave